Drug Profile


Alternative Names: FE-301; FE-999301; TJ-301

Latest Information Update: 22 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Conaris Research Institute
  • Developer Ferring Pharmaceuticals
  • Class Anti-inflammatories; Glycoproteins; Recombinant fusion proteins
  • Mechanism of Action Interleukin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Crohn's disease; Inflammatory bowel diseases

Most Recent Events

  • 08 Aug 2017 Leading Biopharm plans a phase II trial for Ulcerative colitis (NCT03235752)
  • 19 Dec 2016 Olamkicept licensed to IMAB in China
  • 23 Aug 2016 Phase-II clinical trials in Inflammatory bowel disease in Germany (IV) (DRKS00010101)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top